UK-based pharma company AstraZeneca, which is developing the Corona vaccine in collaboration with Oxford University, has voluntarily paused the ongoing trials of the vaccine. A statement has been issued by the company states that one person fell ill during the trials, after which we have decided to pause the trial.
The statement said that this is a routine interruption, as not much information has yet been received about the illness of the person involved in the test. The trial will be carried forward only after reviewing it.
According to the company’s spokesperson, ‘As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow the review of safety data by an independent committee.
This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.’
It has affected the clinical trials of other vaccines:
According to the reports, a moratorium on vaccine testing has affected other AstraZeneca vaccine trials. It has also affected the clinical trials being carried out by other vaccine manufacturers. Now all of them will also be looking for such resolutions so that the proper effect of the vaccine can be understood.
As of now, AstraZeneca has not commented on it yet. However, nine major US and European vaccine developers on Tuesday resolved to maintain scientific safety and efficacy standards for their experimental vaccines, despite the exigency to control the coronavirus epidemic.
9 vaccine candidates in third phase trials:
AstraZeneca started the registration of 30,000 volunteers for the third phase clinical trial from 31 August. AstraZeneca is one of 9 companies whose vaccine trials are in the third or last phase.